eligibility_summary
Adults (≥18) with intermediate/high-grade CD19+ B-cell NHL (DLBCL, MCL, transformed) in first relapse or non-CR after 1st line, candidates for myeloablative HSCT, CMV-seropositive, KPS ≥70, life ≥16 wks, adequate cardiac/pulmonary/renal/hepatic/marrow function, consent/tissue, contraception. Exclude prior transplant, systemic steroids/immunosuppression, recent growth factors/platelets, CNS disease (unless CR), arrhythmia, bleeding disorder, recent stroke, other active cancer, HIV/hepatitis, infection, pregnancy, noncompliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase I single-arm study post-auto-HSCT in intermediate/high-grade B-cell NHL testing: 1) CMV-specific CD19-CAR T cells: autologous, gene-modified T-cell therapy. Mechanism: CAR signaling mediates targeted cytotoxicity against CD19 on malignant B cells, cells retain native CMV-specific TCRs, enabling recall responses. 2) CMV-MVA Triplex vaccine: biological, modified vaccinia Ankara (viral-vector) vaccine encoding CMV antigens, mechanism: boosts CMV-specific T-cell activation to drive in vivo expansion/persistence of the CMV-specific CAR T cells. Cells/pathways targeted: CD19+ B cells, CAR-mediated T-cell cytotoxic pathways, CMV-specific TCR activation via MVA-induced antigen presentation to enhance CAR T function after transplant.